NEW YORK (GenomeWeb News) – Lentigen has signed a contract with the US Army that extends a 2006 agreement that uses the company’s lentiviral vector technology for biodefense, the company said today.
 
The Army will use the lentiviral technology, which is used to deliver genes or gene silencing sequences into cells, at its Edgewood Chemical Biological Center.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.